who received lurbinectedin to assess the efficacy of this new second-line treatment. The results show that lurbinectedin is a wholly acceptable treatment option with seemingly greater efficacy than standard treatments, according to a poster that Nicolas Girard, MD, respiratory medicine specialist and coordinator of the Curie-Montsouris Chest Center in Paris, presented at the ASCO 2023 annual meeting.
Lurbinectedin, a new medicinal product that was developed from a sea creature , is one such option. It proved effective in relapsing small-cell cancer in a. These results led to fast-track approval by the FDA in 2020 and early-access use in France in the same year for adult patients with SCLC whose disease had worsened after platinum-based chemotherapy.
The response rate was 22%, and the disease control rate was 38%. After a median follow-up of 20.8 months, median progression-free survival and overall survival were 1.9 and 4.7 months, respectively. Six-month PFS and OS rates were 7% and 42%, respectively.